Dr. Reddy's Laboratories Ltd.

441 articles about Dr. Reddy's Laboratories Ltd.

• Dr. Reddy's Laboratories Announces Approval for Lenalidomide Capsules from the U.S. Food and Drug Administration (USFDA)

  10/19/2021

  Dr. Reddy’s Laboratories Ltd. announced the final approval of its Abbreviated New Drug Application for Lenalidomide Capsules, in 2.5 mg and 20 mg strengths, and tentative approval for 5 mg, 10 mg, 15 mg, and 25 mg strengths, a therapeutic equivalent generic version of REVLIMID® Capsules, from the U.S. Food and Drug Administration.

• Dr. Reddy's Laboratories Announces the Launch of Carmustine for Injection, USP in the U.S. Market

  10/15/2021

  Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Carmustine for Injection, USP, a therapeutic equivalent generic version of BiCNU® (carmustine for injection) approved by the U.S. Food and Drug Administration (USFDA).

• Dr. Reddy’s Laboratories enters into definitive agreement with Citius Pharmaceuticals, Inc. to sell its rights to anti-cancer agent E7777 (denileukin diftitox)

  9/4/2021

  Dr. Reddy’s Laboratories Ltd., announced that it has entered into a definitive agreement with Citius Pharmaceuticals, Inc. pursuant to which it sold all of its rights to E7777 and certain related assets.

• Dr. Reddy's Laboratories Canada announces the launch of Reddy-Lenalidomide, one of the first generic medications of its kind for the Canadian Market

  9/2/2021

  Dr. Reddy’s Laboratories Ltd. announced that Reddy-Lenalidomide, a generic equivalent to Revlimid® capsules, is approved by Health Canada and has been launched in the Canadian market.

• Dr. Reddy's Laboratories Announces the Launch of Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules, USP in the U.S. Market

  8/31/2021

  Dr. Reddy’s Laboratories Ltd. announced the launch of Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules USP, 5 mg/2.5 mg, a therapeutic equivalent generic version of Librax® approved by the U.S. Food and Drug Administration.

• Dr. Reddy's Laboratories Announces Filing of Annual Report on Form 20-F

  7/1/2021

  Dr. Reddy’s Laboratories Limited announced that its Annual Report on Form 20-F containing its consolidated financial statements for the fiscal year ended March 31, 2021 and prepared in accordance with the International Financial Reporting Standards as issued by the International Accounting Standards Board was filed with the United States Securities and Exchange Commission on June 30, 2021.

• Journey Medical Corporation Enters into a Definitive Agreement with Dr. Reddy’s Laboratories Ltd. to Develop and Commercialize DFD-29 for the Treatment of Rosacea

  6/30/2021

  Journey Medical Corporation, a partner company of Fortress Biotech, Inc., announced an agreement with Dr. Reddy’s Laboratories Ltd. for the collaborative development and commercialization of the DFD-29 program for the treatment of rosacea.

• Dr. Reddy's Laboratories Announces the Launch of Icosapent Ethyl Capsules, 1 Gram in the U.S. Market

  6/22/2021

  Dr. Reddy’s Laboratories Ltd. announced the launch of Icosapent Ethyl Capsules, 1 gram approved by the U.S. Food and Drug Administration.

• Pregene and Dr. Reddy's Announce License Agreement for Anti-BCMA CAR-T PRG1801 in India

  5/13/2021

  Shenzhen Pregene Biopharma and Dr. Reddy's Laboratories announce a license agreement whereby Dr Reddy's will acquire the exclusive rights in the Republic of India for PRG1801, an anti-BCMA CAR-T cell therapy injection based on single domain antibody technology, from Shenzhen Pregene Biopharma.

• Dr. Reddy's Laboratories Announces the Launch of Ertapenem for Injection in the U.S. Market

  5/12/2021

  Dr. Reddy’s Laboratories Ltd. announced the launch of Ertapenem for Injection, 1 g/vial, a therapeutic equivalent generic version of INVANZ for injection, 1 g/vial approved by the U.S. Food and Drug Administration.

• Dr. Reddy's Laboratories Announces the Launch of Albendazole Tablets, USP in the U.S. Market

  4/29/2021

  Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Albendazole Tablets, USP, a therapeutic equivalent generic version of Albenza Tablets, 200 mg, approved by the U.S. Food and Drug Administration (USFDA).

• Dr. Reddy's Laboratories Gets Emergency Use Authorisation for Sputnik V in India

  4/13/2021

  Dr. Reddy’s Laboratories Ltd. announced that it has received the permission from the Drug Controller General of India to import the Sputnik vaccine into India for restricted use in emergency situations as per the provisions of the New Drug and Clinical Trials rules, 2019 under the Drugs and Cosmetics Act.

• Dr. Reddy's Laboratories Announces the Launch of a Generic Version of Sapropterin Dihydrochloride Powder for Oral Solution, 100 mg in the U.S. Market

  4/7/2021

  Dr. Reddy’s Laboratories Ltd. announced the launch of Sapropterin Dihydrochloride Powder for Oral Solution, 100 mg, a therapeutic equivalent generic version of Kuvan® Powder for Oral Solution, 100 mg, USP, approved by the U.S. Food and Drug Administration.

• Dr. Reddy's Laboratories Announces the Launch of Lansoprazole DR Orally Disintegrating Tablets in the U.S. Market

  2/22/2021

  Dr. Reddy’s Laboratories Ltd. announced the launch of Lansoprazole DR Orally Disintegrating Tablets, a therapeutic equivalent generic version of Prevacid SoluTab Delayed-Release Orally Disintegrating Tablets, 15 mg and 30 mg, approved by the U.S. Food and Drug Administration.

• Dr. Reddy's Initiates Process for Emergency Use Authorization of Sputnik V

  2/19/2021

  Dr. Reddy’s Laboratories Ltd. announced that it has initiated the process with the Drugs Controller General of India for Emergency Use Authorization of the well-studied human adenoviral vector-based platform vaccine candidate, Sputnik V.

• Dr. Reddy's Laboratories announces the launch of Fluphenazine Hydrochloride Tablets, USP in the U.S. Market

  2/18/2021

  Dr. Reddy’s Laboratories Ltd. announced the launch of Fluphenazine Hydrochloride Tablets, USP, a therapeutic equivalent generic version of Prolixin Tablets, 1 mg, 2.5 mg, 5 mg, and 10 mg, approved by the U.S. Food and Drug Administration.

• Dr. Reddy's Laboratories Announces the Launch of Capecitabine Tablets, USP in the U.S. Market

  2/17/2021

  Dr. Reddy’s Laboratories Ltd. announced the launch of Capecitabine Tablets, USP a therapeutic equivalent generic version of Xeloda Tablets approved by the U.S. Food and Drug Administration.

• Dr. Reddy's Laboratories Announces the Launch of Vigabatrin Tablets, USP in the U.S. Market

  2/2/2021

  Dr. Reddy’s Laboratories Ltd. announced the launch of Vigabatrin Tablets USP, 500 mg, a therapeutic equivalent generic version of Sabril® Tablets, USP, approved by the U.S. Food and Drug Administration.

• Dr. Reddy’s Q3 & 9M FY21 Financial Results

  1/29/2021

  Dr. Reddy’s Laboratories Ltd. announced its consolidated financial results for the quarter and the nine months ended December 31, 2020.

• Dr. Reddy’s and GRA announces Avigan Pivotal Studies Update

  1/27/2021

  Study for hospitalized moderate to severe cases in Kuwait terminated, while study for out-patient mild to moderate cases continues in North America